You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 21, 2024


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Verapamil Hydrochloride, and what generic alternatives are available?

Verapamil Hydrochloride is a drug marketed by Mylan, Rising, Abraxis Pharm, Acic Pharms, Bedford, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Hospira, Intl Medication, Luitpold, Mankind Pharma, Marsam Pharms Llc, Smith And Nephew, Solopak, Zydus Pharms, Amneal, Caplin, Exela Pharma, Micro Labs, Nephron, Somerset, Somerset Theraps Llc, Apotex Corp, Cadila Pharms Ltd, Glenmark Pharms Ltd, Ivax Sub Teva Pharms, Pliva, Strides Pharma, Sun Pharm Inds Inc, Actavis Elizabeth, Chartwell Rx, Heritage Pharms, Mutual Pharm, Sun Pharm Industries, Warner Chilcott, and Watson Labs. and is included in sixty-five NDAs.

The generic ingredient in VERAPAMIL HYDROCHLORIDE is verapamil hydrochloride. There are seventeen drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Verapamil Hydrochloride

A generic version of VERAPAMIL HYDROCHLORIDE was approved as verapamil hydrochloride by EXELA PHARMA on March 30th, 1984.

  Sign Up

Drug patent expirations by year for VERAPAMIL HYDROCHLORIDE
Recent Clinical Trials for VERAPAMIL HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Benha UniversityN/A
Radboud University Medical CenterPhase 2
Canisius-Wilhelmina HospitalPhase 2

See all VERAPAMIL HYDROCHLORIDE clinical trials

Medical Subject Heading (MeSH) Categories for VERAPAMIL HYDROCHLORIDE
Paragraph IV (Patent) Challenges for VERAPAMIL HYDROCHLORIDE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
VERELAN PM Extended-release Capsules verapamil hydrochloride 100 mg and 200 mg 020943 1 2006-07-20
VERELAN PM Extended-release Capsules verapamil hydrochloride 300 mg 020943 1 2006-05-19

US Patents and Regulatory Information for VERAPAMIL HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Heritage Pharms VERAPAMIL HYDROCHLORIDE verapamil hydrochloride TABLET;ORAL 071881-001 Apr 5, 1988 AB RX No Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Somerset VERAPAMIL HYDROCHLORIDE verapamil hydrochloride SOLUTION;INTRAVENOUS 211035-002 Jun 18, 2018 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Hospira VERAPAMIL HYDROCHLORIDE verapamil hydrochloride SOLUTION;INTRAVENOUS 070738-001 May 6, 1987 AP RX No Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.